Phase 2Recruiting
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (SCALA)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease With Chronic Bronchitis (SCALA)
- Sponsor
- UCB Biopharma SRL (Industry)
- Enrolment
- 402 planned
- Conditions
- Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
- Interventions
- Galvokimig; Placebo
- Ages
- adults, older adults
- Registry
- NCT07725939, CTIS2026-525523-25-00
Full record on ClinicalTrials.gov
From the registry
The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.
Primary outcomes
- Time from treatment assignment to first moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
History
Primary completion expected
Last registry update
Started
Registered